Dr. Reddy's Laboratories Limited (RDY) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Dr. Reddy's Laboratories Limited (RDY) Bundle
Streamline your analysis and improve precision with our (RDY) DCF Calculator! Utilizing real data from Dr. Reddy's Laboratories Limited and customizable assumptions, this tool empowers you to forecast, evaluate, and value (RDY) like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,045.3 | 2,222.4 | 2,511.4 | 2,880.2 | 3,270.1 | 3,678.0 | 4,136.7 | 4,652.6 | 5,232.9 | 5,885.5 |
| Revenue Growth, % | 0 | 8.66 | 13 | 14.69 | 13.54 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| EBITDA | 489.5 | 535.4 | 559.3 | 871.9 | 1,035.8 | 972.7 | 1,094.0 | 1,230.5 | 1,384.0 | 1,556.6 |
| EBITDA, % | 23.93 | 24.09 | 22.27 | 30.27 | 31.67 | 26.45 | 26.45 | 26.45 | 26.45 | 26.45 |
| Depreciation | 146.1 | 149.9 | 138.5 | 148.0 | 173.8 | 219.6 | 247.0 | 277.8 | 312.5 | 351.5 |
| Depreciation, % | 7.14 | 6.74 | 5.52 | 5.14 | 5.32 | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 |
| EBIT | 343.4 | 385.5 | 420.8 | 723.9 | 861.9 | 753.1 | 847.0 | 952.7 | 1,071.5 | 1,205.1 |
| EBIT, % | 16.79 | 17.35 | 16.75 | 25.13 | 26.36 | 20.48 | 20.48 | 20.48 | 20.48 | 20.48 |
| Total Cash | 301.5 | 405.0 | 519.7 | 781.9 | 954.3 | 809.1 | 910.0 | 1,023.5 | 1,151.1 | 1,294.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 589.0 | 581.5 | 782.1 | 849.1 | 940.6 | 1,061.8 | 1,194.2 | 1,343.2 | 1,510.7 | 1,699.1 |
| Account Receivables, % | 28.8 | 26.17 | 31.14 | 29.48 | 28.76 | 28.87 | 28.87 | 28.87 | 28.87 | 28.87 |
| Inventories | 410.8 | 532.0 | 596.1 | 570.1 | 744.4 | 811.5 | 912.7 | 1,026.5 | 1,154.5 | 1,298.5 |
| Inventories, % | 20.08 | 23.94 | 23.73 | 19.79 | 22.77 | 22.06 | 22.06 | 22.06 | 22.06 | 22.06 |
| Accounts Payable | 125.9 | 148.7 | 187.1 | 209.2 | 252.4 | 259.5 | 291.9 | 328.3 | 369.2 | 415.2 |
| Accounts Payable, % | 6.15 | 6.69 | 7.45 | 7.26 | 7.72 | 7.06 | 7.06 | 7.06 | 7.06 | 7.06 |
| Capital Expenditure | -71.6 | -147.1 | -223.1 | -221.0 | -321.4 | -268.5 | -302.0 | -339.7 | -382.1 | -429.7 |
| Capital Expenditure, % | -3.5 | -6.62 | -8.89 | -7.67 | -9.83 | -7.3 | -7.3 | -7.3 | -7.3 | -7.3 |
| Tax Rate, % | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 | 22.52 |
| EBITAT | 371.3 | 234.6 | 307.0 | 539.3 | 667.8 | 581.1 | 653.6 | 735.1 | 826.8 | 929.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -428.1 | 146.5 | -3.9 | 447.4 | 297.7 | 351.1 | 397.3 | 446.9 | 502.6 | 565.3 |
| WACC, % | 6.21 | 5.93 | 6.02 | 6.03 | 6.05 | 6.05 | 6.05 | 6.05 | 6.05 | 6.05 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,877.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 577 | |||||||||
| Terminal Value | 14,248 | |||||||||
| Present Terminal Value | 10,623 | |||||||||
| Enterprise Value | 12,501 | |||||||||
| Net Debt | 151 | |||||||||
| Equity Value | 12,350 | |||||||||
| Diluted Shares Outstanding, MM | 167 | |||||||||
| Equity Value Per Share | 74.08 |
What You Will Receive
- Comprehensive Financial Model: Leverage Dr. Reddy's actual data for accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other vital metrics.
- Real-Time Calculations: Automatic updates provide immediate feedback as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling ongoing use for in-depth forecasts.
Key Features
- Comprehensive RDY Data: Pre-filled with Dr. Reddy's Laboratories' historical financials and future projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures.
- Interactive Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Multiple Scenario Analysis: Develop various forecast scenarios to evaluate different valuation results.
- Intuitive Interface: Designed to be user-friendly for both experienced professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Dr. Reddy's pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions.
Why Choose This Calculator for Dr. Reddy's Laboratories Limited (RDY)?
- User-Friendly Interface: Crafted for both novices and seasoned professionals.
- Customizable Inputs: Effortlessly adjust parameters to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to Dr. Reddy's valuation as you modify inputs.
- Pre-Loaded Data: Comes with Dr. Reddy's actual financial figures for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Dr. Reddy's Laboratories Limited (RDY) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Dr. Reddy's Laboratories Limited (RDY).
- Consultants: Deliver professional valuation insights on Dr. Reddy's Laboratories Limited (RDY) to clients quickly and accurately.
- Business Owners: Understand how large companies like Dr. Reddy's Laboratories Limited (RDY) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Dr. Reddy's Laboratories Limited (RDY).
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Dr. Reddy's Laboratories Limited (RDY).
- Real-World Data: Dr. Reddy's historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables that provide clear, actionable results for decision-making.